# NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/par-22-034-nhlbi-career-transition-award-for-intramural-postdoctoral/  
Official notice: https://www.grants.gov/search-results-detail/336071

> National Institutes of Health offered grants to colleges and universities. Applications closed on July 12, 2024.

| Field | Value |
|---|---|
| Opportunity number | PAR-22-034 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | July 12, 2024 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.233, 93.837, 93.838, 93.839, 93.840 |

## Who can apply

- Public and State controlled institutions of higher education

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. See the funding announcement for eligibility details

## What the grant funds

The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers still in training in the NHLBI Division of Intramural Research the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing to serve as lead investigator of a clinical trial or an ancillary study to an ongoing clinical trial, should apply to the companion FOA, PAR-22-040 "NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22- Clinical Trial Required).

## Questions people ask

### Is PAR-22-034 still open?

No. It closed on July 12, 2024. A newer notice is open: PAR-24-209, due dates in the notice, expires July 12, 2027.

### Who can apply for NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from colleges and universities. The notice adds further conditions, so read its eligibility section.

### What is the deadline for NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)?

Closed July 12, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under PAR-22-034?

NIH RePORTER lists 2 projects funded under PAR-22-034 in fiscal 2025 to 2026, at 2 institutions. The most were at University of Maryland Baltimore, University of Kentucky.

### Who has won Cardiovascular Diseases Research grants before?

The largest recipients over five fiscal years were The Trustees of the University of Pennsylvania, Brigham & Womens Hospital Inc, Regents of the University of Michigan. The program made 11,798 awards worth $15 billion in that time.